Open access

Introductory Chapter: Recent Advances in Systemic Lupus Erythematosus

Written By

Sophia Lionaki and Ioannis Boletis

Published: 25 March 2020

DOI: 10.5772/intechopen.88226

From the Edited Volume

Lupus - New Advances and Challenges

Edited by Sophia Lionaki

Chapter metrics overview

754 Chapter Downloads

View Full Metrics

1. Introduction

Systemic lupus erythematosus is the prototype of autoimmune disorder, which is typically manifesting in multiple organ systems and running a chronic course, affecting primarily females. It is associated with significant public health impact in affected individuals, with highly heterogenous presentation and progression. During the last two decades, substantial progress has been made in our knowledge on systemic lupus erythematosus incidence, pathogenesis, therapeutic interventions, and long-term outcomes. However, it remains a challenging area of research, especially considering the genetic, epigenetic, and environmental factors that have been found to play a crucial role in disease prognosis [1]. Estimates on the worldwide incidence and prevalence of lupus revealed that the highest incidence was found in North America, while the lowest rates have been reported in Northern Australia [2]. Interestingly, a registry from the island of Crete reported that the overall age-adjusted/sex-adjusted incidence is growing among males [3]. Factors such as age, gender, ethnicity, genetics, hormonal status and environmental factors appear to have a central function in the development of the disease [2].


2. The new era of systemic lupus erythematosus

Despite the significant improvements which have been achieved in the field of lupus, including the overall management and immunosuppressive agents used for therapy, mortality rates of affected patients remain three times higher than those in the general population [2]. In particular, patients with lupus nephritis, who end up in end-stage kidney disease, inquire a huge burden of morbidity, related not only to the dialysis procedure but also to the inflammatory background, the impact of cumulative immunosuppression, and the phenomenon of accelerated atherosclerosis which results in cardiovascular death [4]. Still the performance of each patient is variable. For instance, neurologic and psychiatric manifestations of systemic lupus erythematosus appear to have an increasing rate in recent reports although they are found in different frequencies across lupus cohorts, depending on the methodology used to define the related signs/symptoms and the screening practice [5]. Likewise, family planning becomes a crucial problem for women with systemic lupus erythematosus, considering the fact that females of reproductive age are the most frequently affected patients. Pregnancies in patients with active lupus and especially in those with renal involvement have been associated with significant morbidity and mortality for both the mother and the fetus [6]. Moreover, the interplay between environmental factors and the genetic profile of each individual appear to be of great importance with respect to the onset and the progression of this disorder [7, 8]. Given these circumstances, we consider systemic lupus erythematosus a challenging field of research, which enquires continuing updating in order to illustrate all current knowledge regarding disease pathogenesis and provide guidelines for clinical practice employing all newer immunosuppressive agents.


  1. 1. Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Practice & Research. Clinical Rheumatology. 2017;31(3):306-320
  2. 2. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: An update. Current Opinion in Rheumatology. 2018;30(2):144-150
  3. 3. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Practice & Research. Clinical Rheumatology. 2018;32(2):188-205
  4. 4. Mageau A, Timsit JF, Perrozziello A, Ruckly S, Dupuis C, Bouadma L, et al. The burden of chronic kidney disease in systemic lupus erythematosus: A nationwide epidemiologic study. Autoimmunity Reviews. Jul 2019;18(7):733-737. pii: S1568-9972(19)30114-4
  5. 5. Tani C, Palagini L, Moraes-Fontes MF, Carli L, Mauri M, Bombardieri S, et al. Neuropsychiatric questionnaires in systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2014;32(5 Suppl 85):S-59-S-64
  6. 6. Nahal SK, Selmi C, Gershwin ME. Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythematosus. Journal of Autoimmunity. 2018;93:16-23
  7. 7. Javinani A, Ashraf-Ganjouei A, Aslani S, Jamshidi A, Mahmoudi M. Exploring the etiopathogenesis of systemic lupus erythematosus: A genetic perspective. Immunogenetics. 2019;71(4):283-297
  8. 8. Patrias K. Citing Medicine: The NLM Style Guide for Authors, Editors, and Publishers [Internet]. Bethesda, MD: National Library of Medicine (US); 2007. [Updated: 2 October 2015; Cited: 13 October 2016]. Available from:

Written By

Sophia Lionaki and Ioannis Boletis

Published: 25 March 2020